Dyne Therapeutics, Inc.
$23.07▲ 5.87%(+$1.28)
TickerSpark Score
57/100
▌ Mixed
60
Valuation
20
Profitability
20
Growth
84
Health
100
Momentum
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DYN research report →
52-Week Range89% of range
Low
$8.06
Current
$23.07
High
$25.00
Company Overviewwww.dyne-tx.com
About the company
Dyne Therapeutics, Inc. is a U. S.
- CEO
- John G. Cox
- IPO
- 2020
- Employees
- 192
- HQ
- Waltham, MA, US
Price Chart
+158.05% · this period
Valuation
- Market Cap
- $3.81B
- P/E
- -7.16
- P/S
- 0.00
- P/B
- 4.40
- EV/EBITDA
- -7.13
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -58.28%
- ROIC
- -45.57%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-446,214,000 · -40.58%
- EPS
- $-3.47 · -2.97%
- Op Income
- $-468,184,000
- FCF YoY
- -37.45%
Performance & Tape
- 52W High
- $25.00
- 52W Low
- $8.06
- 50D MA
- $18.59
- 200D MA
- $18.03
- Beta
- 1.08
- Avg Volume
- 1.79M
Get TickerSpark's AI analysis on DYN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Form 4 · Filings
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 26, 26 | Rhodes Jason P | sell | 162,954 |
| Jun 29, 26 | Rhodes Jason P | sell | 102,969 |
| Jun 26, 26 | Rhodes Jason P | sell | 81,903 |
| Jun 29, 26 | Rhodes Jason P | sell | 51,756 |
| Jun 26, 26 | Rhodes Jason P | sell | 64,411 |
| Jun 29, 26 | Rhodes Jason P | sell | 40,702 |
| Jun 25, 26 | Lucera Erick | sell | 2,362 |
| Jun 23, 26 | Rhodes Jason P | sell | 77,855 |
| Jun 24, 26 | Rhodes Jason P | sell | 50,530 |
| Jun 25, 26 | Rhodes Jason P | sell | 12,699 |
Coverage · DYN
Our DYN coverage
Recent articles, reports, and earnings notes.
On-Demand Research
No research on DYN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DYN report →Internal Compare
Similar companies
Peers in the same neighborhood.
RARE▲3.37%
Ultragenyx Pharmaceutical Inc.
$33.47
SLNO▲0.00%
Soleno Therapeutics, Inc.
$53.01
CNTA▲0.00%
Centessa Pharmaceuticals plc
$40.50
XENE▲1.09%
Xenon Pharmaceuticals Inc.
$60.96
APGE▲0.11%
Apogee Therapeutics, Inc.
$132.91
AAPG▲3.01%
Ascentage Pharma Group International
$18.50
MIRM▲4.26%
Mirum Pharmaceuticals, Inc.
$125.59
CELC▲3.31%
Celcuity Inc.
$107.95